OralDosed ingredientTherapeutic flag
Cosmetic cross-reference
Spironolactone
CAS 52-01-7
Spironolactone (CAS 52-01-7) is a Phase 4 pharmaceutical compound with 8 bioactivity targets and 7,888 adverse event associations.
SOURCE
NLM DailyMed
Label records
0
SOURCE
EMBL-EBI ChEMBL
Bioactivity
15
SOURCE
DrugCentral
Adverse signals
7,888
SOURCE
IUPHAR/BPS
PubMed IDs
6
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Spironolactone
CAS Number
52-01-7
UNII
27O7W4T232
InChIKey
LXMSZDCAJNLERA-ZHYRCANASA-N
ChEMBL ID
CHEMBL1393
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
AldactazideAldactone
black box warningdosed ingredientnatural productoraltherapeutic flag
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL1393 | Small molecule
SOURCE
Ingredients table / CosIng profile
same-CAS cross-reference
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
SOURCE
EMBL-EBI ChEMBL
15 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 24089.866371681415 nM | 113 | - |
| - | IC50 | 8705.711063829787 nM | 47 | - |
| - | Potency | 18687.151612903224 nM | 29 | - |
| - | Ki | 305.7372222222222 nM | 9 | - |
| - | EC50 | 16660 nM | 5 | - |
| Glucocorticoid receptor Nuclear hormone receptor |
IC50 | 6.227 | - | Homo sapiens |
| Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor |
- | - | - | Homo sapiens |
| Mineralocorticoid receptor Nuclear hormone receptor |
IC50 | 9.884 | - | Homo sapiens |
| Androgen receptor Nuclear hormone receptor |
Ki | 7.4 | - | Homo sapiens |
| Progesterone receptor Nuclear hormone receptor |
EC50 | 6.029 | - | Homo sapiens |
| Estrogen receptor beta Nuclear hormone receptor |
EC50 | 5.48 | - | Homo sapiens |
| Cytochrome P450 2C19 Enzyme |
IC50 | 5.523 | - | Homo sapiens |
| Androgen receptor Transcription factor |
IC50 | 6.17 | - | Rattus norvegicus |
| Progesterone receptor Transcription factor |
Ki | 6.663 | - | Bos taurus |
| Multidrug and toxin extrusion protein 1 Transporter |
IC50 | 4.73 | - | Homo sapiens |
SOURCE
DrugCentral
80 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Hyperkalaemia | 3873 | 5428.386 | 10020646 |
| Acute kidney injury | 5826 | 2775.126 | 10069339 |
| Cardiac failure | 2629 | 1956.249 | 10007554 |
| Hyponatraemia | 2172 | 1176.04 | 10021036 |
| Hepatic encephalopathy | 818 | 1122.821 | 10019660 |
| Drug ineffective | 2115 | 1040.216 | 10013709 |
| Ascites | 1233 | 850.602 | 10003445 |
| Hypotension | 3410 | 809.01 | 10021097 |
| Right ventricular failure | 625 | 743.466 | 10039163 |
| Pulmonary arterial hypertension | 675 | 738.79 | 10064911 |
| Cardiac failure congestive | 1638 | 732.72 | 10007559 |
| Renal impairment | 1703 | 693.475 | 10062237 |
| Oedema peripheral | 2284 | 657.505 | 10030124 |
| Dyspnoea | 5509 | 632.913 | 10013968 |
| Pulmonary hypertension | 830 | 620.033 | 10037400 |
| Synovitis | 15 | 613.958 | 10042868 |
| Pemphigus | 11 | 602.648 | 10034280 |
| Cardiac failure chronic | 413 | 593.675 | 10007558 |
| Arthropathy | 102 | 568.565 | 10003285 |
| Drug interaction | 2900 | 547.338 | 10013710 |
| Renal failure | 1900 | 545.441 | 10038435 |
| Hand deformity | 6 | 539.805 | 10061194 |
| Dehydration | 2099 | 536.746 | 10012174 |
| Systemic lupus erythematosus | 69 | 511.936 | 10042945 |
| Bradycardia | 1303 | 491.403 | 10006093 |
| Joint swelling | 345 | 488.676 | 10023232 |
| Glossodynia | 45 | 476.707 | 10018388 |
| Infusion related reaction | 235 | 472.028 | 10051792 |
| Rheumatoid arthritis | 203 | 462.728 | 10039073 |
| Therapeutic product effect decreased | 108 | 450.282 | 10082201 |
| Drug intolerance | 356 | 444.989 | 10061822 |
| Treatment failure | 151 | 441.546 | 10066901 |
| Blood creatinine increased | 1428 | 440.633 | 10005483 |
| Off label use | 2239 | 421.368 | 10053762 |
| Hepatic cirrhosis | 596 | 420.132 | 10019641 |
| Pain | 1625 | 408.101 | 10033371 |
| International normalised ratio increased | 901 | 405.894 | 10022595 |
| Alopecia | 374 | 404.421 | 10001760 |
| Blood potassium increased | 525 | 402.858 | 10005725 |
| Maternal exposure during pregnancy | 133 | 395.521 | 10071408 |
| Arthralgia | 1214 | 379.903 | 10003239 |
| Hepatic failure | 755 | 378.037 | 10019663 |
| Atrial fibrillation | 1611 | 373.632 | 10003658 |
| Contraindicated product administered | 198 | 363.225 | 10078504 |
| Hypersensitivity | 395 | 354.628 | 10020751 |
| Completed suicide | 175 | 330.093 | 10010144 |
| Blood urea increased | 612 | 329.397 | 10005851 |
| Fluid retention | 788 | 328.873 | 10016807 |
| Drug abuse | 72 | 317.021 | 10013654 |
| Wound | 111 | 314.111 | 10052428 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
IUPHAR/BPS
1 interaction
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| Mineralocorticoid receptor NR3C2 |
Antagonist | 8.630000114440918 pKi | 18038968 |
SOURCE
PharmGKB
23 phenotype rows
Pharmacogenomics
Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.
ACE (PA139) rs4341
Genotypes CG + GG are associated with increased likelihood of diuretic unresponsiveness when treated with furosemide and spironolactone in people with Liver Cirrhosis as compared to genotype CC.
Evidence: -; PMID 21692745
ADD1 (PA31) rs4961
Genotypes GT + TT are associated with increased likelihood of diuretic unresponsiveness when treated with furosemide and spironolactone in people with Liver Cirrhosis as compared to genotype GG.
Evidence: -; PMID 21692745
CYP11B2 (PA134) rs1799998
Genotypes AA + AG are associated with increased likelihood of diuretic unresponsiveness when treated with furosemide and spironolactone in people with Liver Cirrhosis as compared to genotype GG.
Evidence: -; PMID 21692745
ADRB2 (PA39) rs1042713
Genotype GG is associated with increased risk of emergency department and hospital utliization when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failure as compared to genotypes AA + AG.
Evidence: -; PMID 22543981
ADRB1 (PA38) rs1801252
Genotype AA is not associated with risk of emergency department or hospital utliization when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failure as compared to genotypes AG + GG.
Evidence: -; PMID 22543981
ADRB2 (PA39) rs1042714
Genotype CC is not associated with risk of emergency department or hospital utliization when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failure as compared to genotypes CG + GG.
Evidence: -; PMID 22543981
NOS3 (PA254) rs1799983
Genotype TT is associated with increased risk of emergency department utliization when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failure as compared to genotypes GG + GT.
Evidence: -; PMID 22543981
CYP4A11 (PA27118) rs3890011
Genotype CC is associated with decreased response to spironolactone in people with Hypertension as compared to genotypes CG + GG.
Evidence: -; PMID 25064769
ACE (PA139) rs4343
Genotypes AA + AG are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume when treated with spironolactone in people with chronic heart failure as compared to genotype GG.
Evidence: -; PMID 15121491
ACE (PA139) rs1799752
Genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume when treated with spironolactone in people with chronic heart failure as compared to genotype del/del.
Evidence: -; PMID 15121491
ACE (PA139) rs1799752
Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is not associated with risk of emergency department or hospital utliization when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failure as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.
Evidence: -; PMID 22543981
CYP4A11 (PA27118) rs1126742
Genotype AA is not associated with risk of emergency department or hospital utliization when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failure as compared to genotypes AG + GG.
Evidence: -; PMID 22543981
ADRB1 (PA38) rs1801253
Genotype GG is associated with decreased risk of emergency department utliization when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failure as compared to genotypes CC + CG.
Evidence: -; PMID 22543981
CYP4A11 (PA27118) rs1126742
Genotype GG is associated with decreased response to amiloride or spironolactone in people with Hypertension as compared to genotypes AA + AG.
Evidence: -; PMID 25064769
ADRA2C (PA37) rs61767072
Genotype GGGGCGGGGCCG/GGGGCGGGGCCG is not associated with risk of emergency department or hospital utliization when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failure as compared to genotypes GGGGCGGGGCCG/del + del/del.
Evidence: -; PMID 22543981
ACE rs4343
-
Evidence: 3; PMID 1
NOS3 rs1799983
Heart Failure
Evidence: 3; PMID 1
ACE rs1799752
Heart Failure
Evidence: 3; PMID 1
CYP4A11 rs3890011
Hypertension
Evidence: 3; PMID 1
ADD1 rs4961
Liver Cirrhosis
Evidence: 3; PMID 1
ADRB2 rs1042713
Heart Failure
Evidence: 3; PMID 1
ADRB1 rs1801253
Heart Failure
Evidence: 3; PMID 1
CYP4A11 rs1126742
Hypertension
Evidence: 3; PMID 1
SOURCE
NLM RxNorm
6 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| spironolactone | 9997 | SU | MTHSPL |
| Spironolactone | 9997 | SU | MTHSPL |
| SPIRONOLACTONE | 9997 | SU | MTHSPL |
| spironolactone | 9997 | IN | RXNORM |
| Aldactazide | 17276 | BN | RXNORM |
| Aldactone | 151317 | BN | RXNORM |
SOURCE
SIDER
80 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Agranulocytosis | spironolactone | LLT | C0001824 |
| Agranulocytosis | spironolactone | PT | C0001824 |
| Alopecia | spironolactone | LLT | C0002170 |
| Alopecia | spironolactone | PT | C0002170 |
| Amenorrhoea | spironolactone | LLT | C0002453 |
| Amenorrhoea | spironolactone | PT | C0002453 |
| Anaphylactic shock | spironolactone | LLT | C0002792 |
| Anaphylactic shock | spironolactone | PT | C0002792 |
| Ataxia | spironolactone | LLT | C0004134 |
| Ataxia | spironolactone | PT | C0004134 |
| Benign breast neoplasm | spironolactone | LLT | C0346156 |
| Benign breast neoplasm | spironolactone | PT | C0346156 |
| Body temperature increased | spironolactone | LLT | C0015967 |
| Body temperature increased | spironolactone | PT | C0015967 |
| Body temperature increased | spironolactone | PT | C0015967 |
| Breast cancer | spironolactone | PT | C0006142 |
| Breast enlargement | spironolactone | LLT | C2225524 |
| Breast enlargement | spironolactone | PT | C2225524 |
| Breast pain | spironolactone | LLT | C0024902 |
| Breast pain | spironolactone | PT | C0024902 |
| Carcinoma breast | spironolactone | LLT | C0678222 |
| Confusional state | spironolactone | LLT | C0009676 |
| Confusional state | spironolactone | PT | C0009676 |
| Cramp muscle | spironolactone | LLT | C0026821 |
| Cramps of lower extremities | spironolactone | LLT | C0023218 |
| Dermatitis | spironolactone | PT | C0011603 |
| Diarrhoea | spironolactone | LLT | C0011991 |
| Diarrhoea | spironolactone | PT | C0011991 |
| Discomfort | spironolactone | PT | C0234215 |
| Dizziness | spironolactone | LLT | C0012833 |
| Dizziness | spironolactone | PT | C0012833 |
| Drowsiness | spironolactone | LLT | C0013144 |
| Drug eruption | spironolactone | LLT | C0011609 |
| Drug eruption | spironolactone | PT | C0011609 |
| Drug fever | spironolactone | LLT | C1320835 |
| Eosinophilia | spironolactone | LLT | C0014457 |
| Eosinophilia | spironolactone | PT | C0014457 |
| Erectile dysfunction | spironolactone | LLT | C0242350 |
| Erectile dysfunction | spironolactone | PT | C0242350 |
| Erythema multiforme | spironolactone | PT | C0014742 |
| Feeling abnormal | spironolactone | PT | C1443060 |
| Feeling abnormal | spironolactone | PT | C1443060 |
| Gastric haemorrhage | spironolactone | LLT | C0235325 |
| Gastric haemorrhage | spironolactone | PT | C0235325 |
| Gastritis | spironolactone | LLT | C0017152 |
| Gastritis | spironolactone | PT | C0017152 |
| Gastrointestinal disorder | spironolactone | PT | C0017178 |
| Gastrointestinal symptom NOS | spironolactone | LLT | C0426576 |
| Gynaecomastia | spironolactone | LLT | C0018418 |
| Gynaecomastia | spironolactone | PT | C0018418 |
| Headache | spironolactone | LLT | C0018681 |
| Headache | spironolactone | PT | C0018681 |
| Hyperkalaemia | spironolactone | LLT | C0020461 |
| Hyperkalaemia | spironolactone | PT | C0020461 |
| Hypersensitivity | spironolactone | LLT | C0020517 |
| Hypersensitivity | spironolactone | PT | C0020517 |
| Hypertrichosis | spironolactone | LLT | C0020555 |
| Hypertrichosis | spironolactone | PT | C0020555 |
| Ill-defined disorder | spironolactone | PT | C2047937 |
| Lethargy | spironolactone | LLT | C0023380 |
| Lethargy | spironolactone | PT | C0023380 |
| Leukopenia | spironolactone | LLT | C0023530 |
| Leukopenia | spironolactone | PT | C0023530 |
| Malaise | spironolactone | LLT | C0231218 |
| Malaise | spironolactone | PT | C0231218 |
| Menstruation irregular | spironolactone | LLT | C0156404 |
| Menstruation irregular | spironolactone | PT | C0156404 |
| Muscle spasms | spironolactone | PT | C0037763 |
| Muscle spasms | spironolactone | PT | C0037763 |
| Nausea | spironolactone | LLT | C0027497 |
| Nausea | spironolactone | PT | C0027497 |
| Pruritus | spironolactone | LLT | C0033774 |
| Pruritus | spironolactone | PT | C0033774 |
| Rash | spironolactone | LLT | C0015230 |
| Rash | spironolactone | PT | C0015230 |
| Rash erythematous | spironolactone | LLT | C0234913 |
| Rash erythematous | spironolactone | PT | C0234913 |
| Renal failure | spironolactone | LLT | C0035078 |
| Renal failure | spironolactone | PT | C0035078 |
| Renal failure acute | spironolactone | LLT | C0022660 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Spironolactone used for in pharmaceutical contexts?
Spironolactone (CAS 52-01-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Spironolactone?
Spironolactone has 7,888 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Hyperkalaemia, Acute kidney injury, Cardiac failure, Hyponatraemia, Hepatic encephalopathy. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Spironolactone also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Spironolactone with EU status "prohibited".
What clinical phase is Spironolactone in?
Spironolactone is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Spironolactone?
Spironolactone has 15 bioactivity rows in this page query. Rendered target entries include Glucocorticoid receptor, Nuclear receptor subfamily 1 group I member 2, Mineralocorticoid receptor, Androgen receptor, Progesterone receptor.